StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.
Check Out Our Latest Stock Analysis on DRRX
DURECT Price Performance
Hedge Funds Weigh In On DURECT
A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC boosted its position in shares of DURECT Co. (NASDAQ:DRRX – Free Report) by 4.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. 28.03% of the stock is currently owned by institutional investors.
About DURECT
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- Using the MarketBeat Dividend Yield Calculator
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Stock Market Sectors: What Are They and How Many Are There?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Most Effectively Use the MarketBeat Earnings Screener
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.